Predictive factors of biochemical progression in prostate cancer patients treated with intermittent androgen suppression

Author： de la Taille A. Zerbib M. Conquy S. Amsellem-Ouazana D. Thiounn N. Flam T. Saighi D. Debre B.

Publisher： Elsevier

ISSN： 1569-9056

Source： European Urology Supplements, Vol.1, Iss.1, 2002-01, pp. : 135-135

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Androgen independent progression in prostate cancer: Risk factors

By Auzanneau C. Irani J. Dahmani L. Ouaki F. Pires C. Dore B.

European Urology Supplements, Vol. 2, Iss. 1, 2003-02 ,pp. : 26-26

Elsevier

Access to resources Recommend Favorite

Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study

By Higano C.S. Ellis W. Russell K. Lange P.H.

Urology, Vol. 48, Iss. 5, 1996-11 ,pp. : 800-804

Elsevier

Access to resources Recommend Favorite

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report

By Goldenberg S.L. Bruchovsky N. Gleave M.E. Sullivan L.D. Akakura K.

Urology, Vol. 45, Iss. 5, 1995-05 ,pp. : 839-845

Elsevier

Access to resources Recommend Favorite

Intermittent androgen suppression in the management of prostate cancer - a pilot study

By Crook J.M. Szumacher E. Malone S. Huan S. Segal R.

Urology, Vol. 53, Iss. 3, 1999-03 ,pp. : 530-534

Elsevier

Access to resources Recommend Favorite

Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer

By Grossfeld G.D. Chaudhary U.B. Reese D.M. Carroll P.R. Small E.J.

Urology, Vol. 58, Iss. 2, 2001-08 ,pp. : 240-245

Elsevier

Access to resources Recommend Favorite